Skip to main content
Clinical Trials/IRCT20160310026998N12
IRCT20160310026998N12
Recruiting
Phase 3

Assessment of the effect of memantine in the treatment of chemotherapy-induced peripheral neuropathy: double-blind randomized clinical trial

Tabriz University of Medical Sciences0 sites180 target enrollmentTBD

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
chemotherapy-induced peripheral neuropathy in patients with cancer.
Sponsor
Tabriz University of Medical Sciences
Enrollment
180
Status
Recruiting
Last Updated
5 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
5 years ago
Study Type
Interventional
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • People with any malignancy who have had grade 2 or higher neuropathy following chemotherapy

Exclusion Criteria

  • Patients with hypertension
  • Acute heart failure
  • type 1 \& 2 diabetes mellitus
  • peripheral vascular disease
  • 285/5000Patients taking drugs (amantadine, ketamine, dextromethorphan, L\-dopa; dopaminergic, anticholinergic agonists, barbiturates, neuroleptics, IMAO, antispasmodics, dantrolene or baclofen, phenytoinquinotine, cimetidine, ranitidine And warfarin)
  • People of reproductive ages, pregnancy and lactation
  • People taking other neuropathic medications such as gabapentin, pregabalin and dologestin
  • Patients with brain or leptomeningeal metastasis

Outcomes

Primary Outcomes

Not specified

Similar Trials